Opinion|Videos|December 19, 2023
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC
The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.
Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
2
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
3
Clinical Applications and the Future of Remote Endovascular Procedures
4
Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization
5